|
Name |
oxalicine C
|
Molecular Formula | C30H33NO7 | |
IUPAC Name* |
3-hydroxy-7,8a-dimethyl-2',6'-dioxo-2'-(2-oxo-2-pyridin-3-ylethylidene)-3-prop-1-en-2-ylspiro[2,4a,5,8-tetrahydro-1H-naphthalene-8,5'-oxane]-3'-carboxylicacid
|
|
SMILES |
C=C(C)C1(O)CCC2(C)C(CC=C(C)C23C=C(C(=O)O)C(=CC(=O)c2cccnc2)O3)C12CCC(=O)OC2
|
|
InChI |
InChI=1S/C30H33NO7/c1-18(2)29(36)12-11-27(4)24(28(29)10-9-25(33)37-17-28)8-7-19(3)30(27)15-21(26(34)35)23(38-30)14-22(32)20-6-5-13-31-16-20/h5-7,13-16,24,36H,1,8-12,17H2,2-4H3,(H,34,35)/b23-14+/t24-,27+,28-,29+,30-/m0/s1
|
|
InChIKey |
ALNIKYMIHQWGHO-DHVPTYTISA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 519.59 | ALogp: | 4.3 |
HBD: | 2 | HBA: | 7 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 123.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 38 | QED Weighted: | 0.25 |
Caco-2 Permeability: | -5.507 | MDCK Permeability: | 0.00001720 |
Pgp-inhibitor: | 0.045 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.597 | 20% Bioavailability (F20%): | 0.969 |
30% Bioavailability (F30%): | 0.322 |
Blood-Brain-Barrier Penetration (BBB): | 0.155 | Plasma Protein Binding (PPB): | 81.81% |
Volume Distribution (VD): | 1.21 | Fu: | 10.83% |
CYP1A2-inhibitor: | 0.044 | CYP1A2-substrate: | 0.835 |
CYP2C19-inhibitor: | 0.123 | CYP2C19-substrate: | 0.203 |
CYP2C9-inhibitor: | 0.218 | CYP2C9-substrate: | 0.08 |
CYP2D6-inhibitor: | 0.029 | CYP2D6-substrate: | 0.065 |
CYP3A4-inhibitor: | 0.666 | CYP3A4-substrate: | 0.433 |
Clearance (CL): | 1.794 | Half-life (T1/2): | 0.296 |
hERG Blockers: | 0.268 | Human Hepatotoxicity (H-HT): | 0.833 |
Drug-inuced Liver Injury (DILI): | 0.501 | AMES Toxicity: | 0.042 |
Rat Oral Acute Toxicity: | 0.83 | Maximum Recommended Daily Dose: | 0.927 |
Skin Sensitization: | 0.328 | Carcinogencity: | 0.806 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
Respiratory Toxicity: | 0.761 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002411 | 0.575 | D06CNP | 0.262 | ||||
ENC002410 | 0.422 | D02CNR | 0.247 | ||||
ENC002102 | 0.384 | D04GJN | 0.245 | ||||
ENC003611 | 0.379 | D02STN | 0.241 | ||||
ENC002080 | 0.357 | D0N0RU | 0.232 | ||||
ENC003423 | 0.353 | D06CWH | 0.229 | ||||
ENC002412 | 0.353 | D0V4WD | 0.228 | ||||
ENC002118 | 0.344 | D0Q4SD | 0.227 | ||||
ENC003422 | 0.336 | D0X4RS | 0.227 | ||||
ENC002044 | 0.292 | D0EP0C | 0.224 |